The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued products.

GlobalData tracks 105 drugs in development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) by 89 companies/universities/institutes. The top development phase for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) is phase ii with 38 drugs in that stage. The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline has 84 drugs in development by companies and 21 by universities/ institutes. Some of the companies in the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline products market are: Bristol-Myers Squibb, Henan Provincial People’s Hospital and Pfizer.

The key targets in the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline products market include Bcr-Abl Tyrosine Kinase (EC 2.7.10.2), Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19), and Cells Expressing B Cell Receptor CD22 (B Lymphocyte Cell Adhesion Molecule or Sialic Acid Binding Ig Like Lectin 2 or T Cell Surface Antigen Leu 14 or CD22).

The key mechanisms of action in the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline product include Bcr-Abl Tyrosine Kinase (EC 2.7.10.2) Inhibitor with 23 drugs in Pre-Registration. The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline products include 11 routes of administration with the top ROA being Oral and 11 key molecule types in the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline products market including Small Molecule, and Cell Therapy.

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) overview

Chronic myeloid leukemia (CML), also known as chronic myelocytic leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age, and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen, and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation, and chemotherapy.

For a complete picture of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.